Coeptis Therapeutics Warrants
COEPW
COEPW was delisted on the 24th of April, 2026.
20 hedge funds and large institutions have $1.84M invested in Coeptis Therapeutics Warrants in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
5% less funds holding
Funds holding: 21 → 20 (-1)
36% less capital invested
Capital invested by funds: $2.87M → $1.84M (-$1.03M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$60.2K |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
+$3.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$49K |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$33.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$5.7K |
| 5 |
ICM
Ionic Capital Management
New York
|
-$3.31K |
COEPW Hedge Fund Activity: Q3 2021 in Review
20 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q3 2021, worth a combined $1.84M — down 36% from $2.87M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of COEPW and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Basso Capital Management, adding an estimated $60.2K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $49K sold.
- 20 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q3 2021, down from 21 in Q2 2021.
- Funds reported $1.84M of Coeptis Therapeutics Warrants stock for Q3 2021, down 36% quarter-over-quarter.
- 1 fund opened new Coeptis Therapeutics Warrants positions in Q3 2021 and 2 closed out, a net change of -1 holder.
- The largest Coeptis Therapeutics Warrants buyer in Q3 2021 was Basso Capital Management, an estimated $60.2K added.
- The largest Coeptis Therapeutics Warrants seller in Q3 2021 was Hudson Bay Capital Management, an estimated $49K sold.
Based on aggregated 13F filings for Q3 2021.